Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tripotassium dicitrato bismuthate/tetracycline/metronidazole - Adare Pharmaceuticals

Drug Profile

Tripotassium dicitrato bismuthate/tetracycline/metronidazole - Adare Pharmaceuticals

Alternative Names: Biskalcitrate potassium 140mg/metronidazole 125mg/tetracycline hydrochloride 125mg; Bismuth subcitrate/metronidazole/tetracycline - Adare Pharmaceuticals; Bismuth-based triple therapy - Adare Pharmaceuticals; Bismuth/metronidazole/tetracycline; Helicide; Helizide; Pylera

Latest Information Update: 23 Feb 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Axcan Pharma
  • Developer Adare Pharmaceuticals
  • Class Cytoprotectives; Helicobacter pylori eradication therapies; Nitroimidazoles; Organometallic compounds; Tetracyclines
  • Mechanism of Action DNA synthesis inhibitors; Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Helicobacter infections

Most Recent Events

  • 30 Jun 2022 AbbVie and Laboratories Juvise Pharmaceuticals (Juvise) enter into an asset purchase agreement for Tripotassium dicitrato bismuthate/tetracycline/metronidazole
  • 01 Mar 2022 Tripotassium dicitrato bismuthate/tetracycline/metronidazole is not yet available for Helicobacter infections in Bulgaria, Greece, Hungary, Italy, Slovakia (NDR Batch 21)
  • 05 Jul 2019 Tripotassium dicitrato bismuthate/tetracycline/metronidazole is not yet available for Helicobacter infections (Combination therapy) in Belgium, United Kingdom, Canada
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top